Aortic Valve Reconstruction With Autologous Pericardium Versus a Bioprosthesis: The Ozaki Procedure in Perspective
Journal of the American Heart Association · 2023
DOI: 10.1161/jaha.122.027391 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, 2023. Verfasst von Shinya Unai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Cardiovascular Surgery Heart, Vascular, and Thoracic Institute Cleveland Clinic Cleveland OH. Hauptthemen laut MEDLINE: Bioprosthesis, Heart Valve Prosthesis Implantation, Heart Valve Prosthesis, Aortic Valve Insufficiency. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
We assessed the Ozaki procedure, aortic valve reconstruction using autologous pericardium, with respect to its learning curve, hemodynamic performance, and durability compared with a stented bioprosthesis. Methods and Results From January 2007 to January 2016, 776 patients underwent an Ozaki procedure at Toho University Ohashi Medical Center. Learning curves, aortic regurgitation (AR), and peak gradient, assessed by serial echocardiograms, valve rereplacement, and survival were investigated. Valve performance and durability were compared with 627 1:1 propensity‐matched patients receiving stented bovine pericardial valves implanted from 1982 to 2011 at Cleveland Clinic. Learning curves were observed for aortic clamp and cardiopulmonary bypass times, AR prevalence, and early mortality. Decreased aortic clamp time was observed over the first 300 cases. New surgeons performing parts of the procedure after case 400 resulted in a slight increase in aortic clamp and cardiopulmonary bypass times. Among matched patients, the Ozaki cohort had more AR than the PERIMOUNT cohort (severe AR at 1 and 6 years, 0.58% and 3.6% versus 0.45% and 1.0%, respectively; P [trend]=0.006), although with a steep learning curve. Peak gradient showed the opposite trend: 14 and 17 mm Hg for Ozaki and 24 and 28 mm Hg for PERIMOUNT at these times ( P [trend] < 0.001). Freedom from rereplacement was similar ( P =0.491). Survival of the Ozaki cohort was 85% at 6 years.
Conclusions
Patients undergoing the Ozaki procedure had lower gradients but more recurrent AR than those receiving PERIMOUNT bioprostheses. Although recurrent AR is concerning, results confirm low risk and good midterm performance of the Ozaki procedure, supporting its continued use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic and Cardiovascular Surgery Heart, Vascular, and Thoracic Institute Cleveland Clinic Cleveland OH.
- Department of Cardiovascular Surgery Toho University Ohashi Medical Center Tokyo Japan.
- Department of Quantitative Health Sciences Lerner Research Institute Cleveland Clinic Cleveland OH.
ORCID-Profile: Shinya Unai, Shigeyuki Ozaki, Tomohiro Saito, Lars G Svensson, Eugene H Blackstone
Zitieren
APA
Unai, S., Ozaki, S., Johnston, D. R., Saito, T., Rajeswaran, J., Svensson, L. G., Blackstone, E. H., & Pettersson, G. B. (2023). Aortic Valve Reconstruction With Autologous Pericardium Versus a Bioprosthesis: The Ozaki Procedure in Perspective. Journal of the American Heart Association. https://doi.org/10.1161/jaha.122.027391
Vancouver
Unai S, Ozaki S, Johnston DR, Saito T, Rajeswaran J, Svensson LG, et al. Aortic Valve Reconstruction With Autologous Pericardium Versus a Bioprosthesis: The Ozaki Procedure in Perspective. Journal of the American Heart Association. 2023. doi:10.1161/jaha.122.027391
BibTeX
@article{Unai2023,
author = {Unai, Shinya and Ozaki, Shigeyuki and Johnston, Douglas R and Saito, Tomohiro and Rajeswaran, Jeevanantham and Svensson, Lars G and Blackstone, Eugene H and Pettersson, Gösta B},
title = {Aortic Valve Reconstruction With Autologous Pericardium Versus a Bioprosthesis: The Ozaki Procedure in Perspective},
journal = {Journal of the American Heart Association},
year = {2023},
doi = {10.1161/jaha.122.027391}
}
EUVIMED